Generic cimetidine
This article was originally published in The Tan Sheet
Executive Summary
Mylan receives first tentative ANDA for cimetidine 200, 300, 400 and 800 mg tablets -- the generic equivalent of SmithKline Beecham's ulcer drug Tagamet -- on Oct. 22. SmithKline does not lose patent protection on Tagamet until May 17, 1994. At an April 1991 presentation to securities analysts, SB said it planned a three-pronged strategy to extend the cimetidine franchise: an OTC version; line extensions; and finding partners to market the drug in generic versions. The firm said it is still in discussions with FDA about OTC cimetidine following a Sept. 9 FDA advisory committee meeting that concluded that the drug's efficacy in treating heartburn is not supported by data ("The Tan Sheet" Sept. 13, p. 1).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning